Leiomyosarcoma: a rare malignant transformation of a uterine leiomyoma

The malignant transformation of a uterine leiomyoma is still debated and, if it occurs, it is very rare. The case of a patient affected by one small leiomyoma is described. Diagnosis was made postoperatively on histopathological examination. The case reported here is meant to underline the need to keep all uterine myomas in check since the transition into leiomyosarcomas (LMSs) may occur with an evolution over a time period which has not been established so far. Specific receptors for luteinizing hormone / human chorionic gonadotropin (LH/hCG) have also been identified in the myometrium of several animal species, including humans. Conventional LMSs express estrogen receptors (ER), progesterone receptors (PR), and androgen receptors (AR) in 30-40% of cases. In comparison with other more common uterine malignancies, uterine LMSs bear some resemblance to type 2 endometrial carcinomas and high-grade serous carcinomas of ovary/fallopian tube origin, based on their genetic instability, frequent p53 abnormalities, aggressive behavior, and resistance to chemotherapy. It could be useful to understand with further researches if hormonal stimulation could be a contributing factor of uterine leiomyoma transformation into LMS. Until today the oncogenic mechanisms underlying the development of uterine LMSs remain elusive.

Leiomysarcoma; Uterus; Leiomyoma; Ovarian stimulation.

[1] Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L., et al.: “Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group study”. Cancer, 1993, 71, 1702.

[2] Giuntoli R.L. 2nd, Metzinger D.S., DiMarco C.S., Cha S.S., Sloan J.A., Keeney G.L., Gostout B.S.: “Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy”. Gynecol. Oncol., 2003, 89, 460.

[3] Veras E., Zivanovic O., Jacks L., Chiappetta D., Hensley M., Soslow R.: “Low-grade leiomyosarcoma” and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas”. Am. J. Surg. Pathol., 2011, 35, 1626.

[4] Atkins K.A., Arronte N., Darus C.J., Rice L.W.: “The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors”. Am. J. Surg. Pathol., 2008, 32, 98.

[5] Bell S.W., Kempson R.L., Hendrickson M.R.: “Problematic uterine smooth muscle neoplasms: a clinicopathologic study of 213 cases”. Am. J. Surg. Pathol., 1994, 18, 535.

[6] Berretta R., Rolla M., Merisio C., Giordano G., Nardelli G.B.: “Uterine smooth muscle tumor of uncertain malignant potential: a threecase report”. Int. J. Gynecol. Cancer, 2008, 18, 1121.

[7] Guntupalli S.R., Ramirez P.T., Anderson M.L., Milam M.R., Bodurka D.C., Malpica A.: “Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis”. Gynecol. Oncol., 2009, 113, 324.

[8] D’Angelo E., Prat J.: “Uterine sarcomas: a review”. Gynecol. Oncol., 2010, 116, 131.

[9] Canciani G.N., Burbos N., Duncan T.J., Lonsdale R., Nieto J.J.: “Late Presentation of metastatic smooth muscle neoplasm of the uterus with low malignant potential”. J. Gynecol Oncol., 2012, 23, 69.

[10] King M.E., Dickersin G.R., Scully R.E.: “Myxoid leiomyosarcoma of the uterus. A report of six cases”. Am. J. Surg. Pathol., 1982, 6, 589.

[11] “World Health Organization classification of tumours”. In: Tavassoli F.A., Devilee P., (eds). Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003.

[12] Mayerhofer K., Obermair A., Windbichler G., Petru E., Kaider A., Hefler L., et al.: “Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases”. Gynecol. Oncol., 1999, 74, 196.

[13] Bodner-Adler B., Bodner K., Czerwenka K., Kimberger O., Leodolter S., Mayerhofer K.: “Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis”. Gynecol. Oncol., 2005, 96, 62.

[14] Chen L., Yang B.: “Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors”. Int. J. Gynecol. Pathol., 2008, 27, 326.

[15] Mittal K., Demopoulos R.I.: “MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors”. Hum. Pathol., 2001, 32, 984.

[16] O’Neill C.J., McBride H.A., Connolly L.E., McCluggage W.G.: “Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential”. Histopathology, 2007, 50, 851.

[17] Jeffers M.D., Farquharson M.A., Richmond J.A., McNicol A.M.: “P53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus”. J. Pathol., 1995, 177, 65.

[18] Akhan S.E., Yavuz E., Tecer A., Iyibozkurt C.A., Topuz S., Tuzlali S., et al.: “The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study”. Gynecol. Oncol., 2005, 99, 36.

[19] Raspollini M.R., Pinzani P., Simi L., Amunni G., Villanucci A., Paglierani M., Taddei G.L.: “Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT”. Gynecol. Oncol., 2005, 98, 334.

[20] Reshef E., Lei Z.M., Rao C.V., Pridham D.D., Chegini N., Luborsky J.L.: “The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua”. J. Clin. Endocrinol. Metab., 1990, 70, 421.

[21] Bhattacharya S., Banerjee J., Sen S., Manna P.R.: “Human chorionic gonadotropin binding sites in the human endometrium”. Acta Endocrinologica, 1993, 129, 15.

[22] Han S.W., Lei Z.M., Rao C.V.: “Homologous downregulation of luteinizing hormone/chorionic gonadotropin receptors by increasing the degradation of receptor transcripts in human uterine endometrial stromal cells”. Biol. Reprod., 1997, 57, 158.

[23] Raga F., Casañ E.M., Kruessel J.S., Wen Y., Huang H.Y., Nezhat C., Polan M.L.: “Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle”. Biol. Reprod., 1998, 59, 661.

[24] Hirakawa T., Galet C., Ascoli M.: “MA-10 cells transfected with the human lutropin/choriogonadotropin receptor (hLHR): a novel experimental paradigm to study the functional properties of the hLHR”. Endocrinology, 2002, 143, 1026.

[25] Stepien A., Ziecik A.J.: “Second messenger systems in the action of LH and oxytocin on porcine endometrial cells in vitro”. Theriogenology, 2002, 57, 2217.

[26] Shemesh M.: “Actions of gonadotrophins on the uterus”. Reproduction, 2001, 121, 835.